Detalles de la búsqueda
1.
Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.
Proc Natl Acad Sci U S A
; 111(51): 18207-12, 2014 Dec 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-25489108
2.
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
J Infect Dis
; 213(12): 1946-54, 2016 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26908741
3.
Molecular and Physicochemical Factors Governing Solubility of the HIV gp41 Ectodomain.
Biophys J
; 111(4): 700-709, 2016 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-27558714
4.
Secondary structure analysis of HIV-1-gp41 in solution and adsorbed to aluminum hydroxide by Fourier transform infrared spectroscopy.
Biochim Biophys Acta
; 1774(3): 351-8, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317342
5.
Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.
AIDS Res Hum Retroviruses
; 23(9): 1105-13, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17919105
6.
Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
AIDS
; 19(3): 279-86, 2005 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-15718838
7.
Assessment of mucosal immunity to HIV-1.
Expert Rev Vaccines
; 9(4): 381-94, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20370549
8.
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
AIDS
; 22(11): 1313-22, 2008 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-18580611
9.
Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).
Vaccine
; 23(34): 4292-301, 2005 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-15927325
10.
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
J Infect Dis
; 192(4): 607-17, 2005 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16028129
11.
HIV-1 gp41 and gp160 are hyperthermostable proteins in a mesophilic environment. Characterization of gp41 mutants.
Eur J Biochem
; 271(8): 1566-79, 2004 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15066182
12.
Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
Vaccine
; 22(20): 2626-30, 2004 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-15193388
13.
Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults.
J Acquir Immune Defic Syndr
; 32(1): 9-17, 2003 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12514409
14.
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
J Infect Dis
; 189(7): 1221-31, 2004 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15031791
15.
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
J Infect Dis
; 190(4): 702-6, 2004 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15272397
16.
Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy.
J Virol
; 76(5): 2206-16, 2002 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-11836398
17.
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
J Infect Dis
; 186(9): 1242-52, 2002 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12402193
Resultados
1 -
17
de 17
1
Próxima >
>>